Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9345760 | 0.82 | OPRD1 (0.46) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL22950459 | 0.81 | OPRD1 (0.45) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL29662090 | 0.81 | OPRD1 (0.45) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL29662060 | 0.80 | GPR119 (0.41) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL22950325 | 0.80 | GPR119 (0.41) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL29508609 | 0.79 | GPR119 (0.44) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL9348476 | 0.77 | ALDH1A1 (0.47) | OPRD1OPRK1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL29662079 | 0.77 | ALDH1A1 (0.47) | OPRD1OPRK1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL27619332 | 0.74 | GPR119 (0.48) | JAK2JAK1GPR119ALDH1A1CYP2C19 | |
| SCHEMBL1489139 | 0.74 | OPRD1 (0.44) | OPRD1OPRK1JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802549-B1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3802549-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3601282-A1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| WO-2019228940-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-05 | — | — | WO | disclosed |
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2018178041-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | OPRD1 331/4885OPRK1 198/4885JAK2 93/4885 |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | OPRD1 331/4885OPRK1 198/4885JAK2 93/4885 |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, KYNU | OPRD1 348/4885OPRK1 231/4885JAK2 129/4885 |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | O60361, ARG1, QDPR | OPRD1 130/4885OPRK1 145/4885JAK2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.